|Thrombotargets and Specs to start Hit to Lead
Thrombotargets Corp. and Specs achieve first milestone in their Drug Discovery collaboration and announce the beginning of a new Anticoagulant program.
North Carolina, April 23rd, 2007. - Since Specs (Delft, The Netherlands) and Thrombotargets Corp (Durham, NC) announced their Drug Discovery Collaboration Agreement, in 2006, Thrombotargets has carried out the HTS of specific library provided by Specs with its powerful and innovative BioPlatformScreen(TM) technology. Thrombotargets has been able to identify some new anticoagulant small molecules.
|published on: 27-Apr-07|